Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire NEW YORK, Jan. 6, 2020 NEW YORK, Jan. 6, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities...
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc. PR Newswire NEW YORK, Dec. 12, 2019 NEW YORK, Dec. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary...
- ARQ 531 demonstrates substantial anti-tumor activity and manageable safety profile - Eight of nine evaluable CLL patients initially dosed at ≥65 mg experienced a Partial Response (PR) - Five of...
(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price? PR Newswire SAN DIEGO, Dec. 9, 2019 SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Shareholder rights law...
Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Merck (NYSE: MRK), known as MSD outside the United States...
Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m. EST ArQule management to hold an Investor Event on Monday, December 9, 2019 from 8:00-10:00...
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London...
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19th, the...
Conference call scheduled today at 9:00 a.m. ET ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the...
Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of tumor mutational status and could be used to predict treatment response...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
